Search Results
May 07, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
progressing well in the Phase 3 PEAK and PINNACLE studies of KSI-101 in patients with macular edema secondary to inflammation (MESI), evaluating the 5 mg and 10 mg dose levels.Topline results from PEAK are expected in 4Q 2026.Topline results from PINNACLE are expected in 2Q 2027.On
More news about: Kodiak Sciences Inc.
May 07, 2026, 10:01 ET AIKO obtiene la elegibilidad para el IVA francés del 5,5% bajo la estricta norma de carbono PPE2 V2
equivalente por kWc, calculado según la metodología PPE2 V2; este es el requisito más difícil de cumplir.Límites de materiales: Plata < 14 mg/W, plomo < 0,1%, cadmio < 0,01%.Trazabilidad completa: El lugar de producción, el origen del silicio y la cadena de fabricación están
More news about: AIKO
May 07, 2026, 10:00 ET Ultra Launches Sleep Pouches: A Six-Ingredient, Clinically-Backed Sleep Stack You Can Feel in as Little as 5-10 Minutes
contains:1 mg Melatonin — Signals the brain that it's time to sleep and supports circadian rhythm regulation.50 mg L-Theanine — Promotes calm alpha brain waves and reduces racing thoughts without sedation.30 mg Magnesium Gluconate — Supports
More news about: Ultra
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
18.57%, to close at $5.50 per share on March 5, 2026. Then, on March 30, 2026, PepGen issued a press release announcing "clinical data from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1 (DM1)." Although PepGen
More news about: Pomerantz LLP
May 07, 2026, 09:01 ET 再鼎醫藥公布 2026年第一季度財務業績和近期公司進展
伴腦轉移的SCLC：Zoci顯示經確認的顱內客觀緩解率（iORR）為53.7%，其中在1.6 mg/kg劑量下達到62.5%（10/16），包括完全緩解。值得注意的是，在既往未接受過腦部放療的患者中也觀察到了緩解（9/15，60%），凸顯了這款藥物對顱內病灶的淨效應。Zoci耐受性良好，總人群≥3級的治療相關不良事件 （TRAEs）發生率為19.9%（27/136），而接受1.6mg/kg劑量的患者為16.4%（9/55）。epNECs：觀察到令人鼓舞的抗腫瘤活性，在不同原發部位的epNEC腫瘤中，經確認的客觀緩解率為38.2%。epNEC中的安全性特征與既往在SCLC中觀察到的一致，1b期患者中≥3級TRAEs發生率為15.2%。
More news about: 再鼎醫藥
May 07, 2026, 07:00 ET Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. AlopeciaIn
More news about: Insmed Incorporated
May 07, 2026, 07:00 ET Wegovy® access expanded for Medicare beneficiaries living with obesity through the Medicare GLP-1 Bridge starting July 1, 2026
medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203.Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.Centers for Disease Control and Prevention.
More news about: Novo Nordisk
May 07, 2026, 06:59 ET Viatris Reports First-Quarter 2026 Financial Results
Company announced that Japan's Ministry of Health, Labour and Welfare approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor, for the treatment of adults with generalized anxiety disorder.2026
More news about: Viatris Inc.
May 07, 2026, 04:23 ET AIKO Secures French 5.5% VAT Eligibility Under Stringent PPE2 V2 Carbon Standard
equivalent per kWc, calculated under PPE2 V2 methodology – the most difficult requirement to achieveMaterial limits: Silver < 14 mg/W, lead < 0.1%, cadmium < 0.01%Full traceability: Production site, silicon origin, and manufacturing chain documented and auditable,
More news about: AIKO
May 06, 2026, 18:15 ET Frasle Mobility reports net revenue of R$ 1.2 billion in the first quarter of 2026
several factors. On the domestic front, the quarter included operational adjustments, such as the completion of the ERP system upgrade at the Extrema (MG) plant, as well as the start of operations of the new 4Mobility logistics automation system. The external environment also pressured the Company's profitability,
More news about: Frasle Mobility
May 06, 2026, 18:10 ET Frasle Mobility alcanza ingresos netos de R$ 1,2 mil millones en el primer trimestre de 2026
factores. En el ámbito interno, el trimestre concentró ajustes operativos, como la finalización de la actualización del sistema ERP en la unidad de Extrema (MG), además del inicio de operaciones del nuevo sistema de automatización logística 4Mobility. El entorno externo también presionó la rentabilidad de la
More news about: Frasle Mobility
May 06, 2026, 16:54 ET Novo Nordisk lança no Brasil terapia semanal para crianças e adultos com deficiência do hormônio do crescimento
mais de 2 mil funcionários. Está presente em dois estados, com um escritório administrativo em São Paulo (SP) e um site produtivo em Montes Claros (MG). Para mais informações, visite www.novonordisk.com.br e siga nossos perfis
More news about: Novo Nordisk
May 06, 2026, 12:10 ET 19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
advantage is even more pronounced. The proportion of participants achieving ≥5% weight loss from baseline reached 84.7%, 89.8%, and 94.6% in the 5 mg, 10 mg, and 15 mg dose groups, respectively.
More news about: BrightGene
May 06, 2026, 11:16 ET STORM Launches Nationwide, Redefining Energy for a New Generation
STORM, where performance meets lifestyle, and communities are formed through shared values and aspirations.Each 12 oz. can of STORM delivers 200mg of caffeine to enhance focus and sustain energy when you need it, combined with a zero-sugar formula for a delicious yet guilt-free experience. Designed
More news about: STORM
May 06, 2026, 10:23 ET FullWell Launches Strawberry-Flavor Capsule-Free Prenatal Stick Packs
(275 mg), vitamin D (100 mcg (4000 IU)), vitamin E (100 mg), thiamin (5 mg), riboflavin (10 mg), niacin (25 mg NE), vitamin B6 (10 mg), folate (1360 mcf DFE), vitamin B12 (150 mcg), biotin (500 mcg), pantothenic acid (150 mg), choline (300 mg), calcium (400 mg), iodine (250 mg), magnesium (300 mg), zinc20
More news about: FullWell
May 06, 2026, 09:00 ET Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection. Learn more Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or
More news about: Eli Lilly and Company
May 06, 2026, 09:00 ET Melting Forest Launches at The Drop, by GNC with Functional Energy & D-Stress
Melting Forest touts zero-sugar sparkling mushroom functional beverages, formulated for either uplift or relaxation. The Energy line delivers 150 mg of caffeine with just 5 calories to support focus and activity, while D-Stress is caffeine-free and designed to promote calm with elevated L-theanine.
More news about: GNC
May 06, 2026, 08:30 ET Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
risk-reduction therapy. In the KARISMA Endoxifen trial, both the 1 mg and 2 mg Endoxifen dose levels produced statistically significant reductions in MBD compared with placebo. The 1 mg dose reduced MBD by 19.3% versus placebo (p=0.004), while the 2 mg dose reduced MBD by 26.5% (p<0.001) versus placebo.
More news about: Atossa Therapeutics Inc
May 06, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL. Please see full
More news about: Neurocrine Biosciences, Inc.
May 06, 2026, 08:00 ET Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.
May 06, 2026, 00:00 ET Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
baseline of -0.72 mmol/L [-2.22 mg/dL] vs. -0.70 mmol/L [-2.17 mg/dL]), respectively; the upper bound of the 95% confidence interval (CI) for the between-group difference (0.06 mmol/L [0.20 mg/dL]) was below the pre-defined non-inferiority margin of 0.19 mmol/L (0.59 mg/dL), demonstrating that AP301 met
More news about: Alebund Pharmaceuticals
May 05, 2026, 20:28 ET MingMed Biotechnology présente des données positives de phase II sur le QA102 oral pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) intermédiaire lors de la réunion 2026 de l'Association for Research in Vision and Ophthalmology (ARVO)
recevoir QA102 par voie orale à une dose de 200 mg ou 400 mg, ou un placebo, deux fois par jour (BID) pendant une durée maximale de 15 mois. Après 12 mois de traitement, le changement moyen du volume des drusen a été réduit de 59,2 % dans le groupe QA102 à 400 mg par rapport au groupe placebo. Bien que le
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
subjects with intermediate atrophic AMD randomized 1:1:1 to oral QA102 200 or 400 mg, or placebo BID for up to 15 months. Following 12-month treatment, the mean change in drusen volume was reduced by 59.2% in QA102 400 mg group relative to the placebo group. Although the primary efficacy endpoint did not
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
subjects with intermediate atrophic AMD randomized 1:1:1 to oral QA102 200 or 400 mg, or placebo BID for up to 15 months. Following 12-month treatment, the mean change in drusen volume was reduced by 59.2% in QA102 400 mg group relative to the placebo group. Although the primary efficacy endpoint did not
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology präsentiert auf der Tagung der Association for Research in Vision and Ophthalmology (ARVO) 2026 positive Phase-II-Daten zum oralen Wirkstoff QA102 für die Behandlung der intermediären altersbedingten Makuladegeneration (AMD)
randomisiert wurden und bis zu 15 Monate lang zweimal täglich entweder 200 oder 400 mg QA102 oral oder Placebo erhielten. Nach einer 12-monatigen Behandlung war die mittlere Veränderung des Drusenvolumens in der QA102-400-mg-Gruppe im Vergleich zur Placebo-Gruppe um 59,2 % reduziert. Obwohl der primäre Wirksamkeitsendpunkt
More news about: MingMed Biotechnology Co., Ltd